IP Library › Patent Application 15030464
Patent Application
App. No. 15/030,464

Therapeutic Agent for Ocular Disease or Prophylactic Agent for Ocular Disease

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/030,464
Abstract

Because 3-[(3S, 4R)-3-Methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile suppresses an increase of the retinal vascular permeability induced by VEGF, it can be used as an active ingredient of a therapeutic or preventive agent for various eye diseases involving VEGF, such as age-related macular degeneration, diabetic retinopathy, macular edema, neovascular maculopathy, retinal vein occlusion and neovascular glaucoma.

Claims (10)

1 . A method for treating or preventing an eye disease selected from the group consisting of age-related macular degeneration, diabetic retinopathy, macular edema, retinal vein occlusion, neovascular maculopathy and neovascular glaucoma in a human subject in need thereof, comprising administering to the human subject an effective amount of a compound represented by the following chemical structural formula:

or a pharmaceutically acceptable salt thereof.

2 . The method according to claim 1 , wherein the age-related macular degeneration is exudative age-related macular degeneration.

3 . The method according to claim 1 , wherein the macular edema is diabetic macular edema or macular edema following branch retinal vein occlusion.

4 . The method according to claim 1 , wherein the retinal vein occlusion is central retinal vein occlusion.

5 . The method according to claim 1 , wherein the compound or pharmaceutically acceptable salt thereof is orally administered.

6 . The method according to claim 1 , wherein the compound or pharmaceutically acceptable salt thereof is administered to an eye of the human subject.

7 . The method according to claim 6 , wherein the compound or pharmaceutically acceptable salt thereof is administered to a vitreous body of the eye.

8 . The method according to claim 6 , wherein the compound or pharmaceutically acceptable salt thereof is injected into the eye.

9 . The method according to claim 7 , wherein the compound or pharmaceutically acceptable salt thereof is injected into the eye.

Assignments (2)
CHANGE OF ADDRESS Recorded Apr 9, 2021
From: JAPAN TOBACCO INC.
To: JAPAN TOBACCO INC.
Reel/Frame 056797/0633 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2016
From: OKIGAMI, HIROMI; KUROSE, TATSUJI; FUJISAWA, KOUSHI; KIKKAWA, CHINAMI
To: JAPAN TOBACCO INC.
Reel/Frame 039815/0068 →